US20060281712A1 - Pyrimidine compounds - Google Patents

Pyrimidine compounds Download PDF

Info

Publication number
US20060281712A1
US20060281712A1 US11/451,897 US45189706A US2006281712A1 US 20060281712 A1 US20060281712 A1 US 20060281712A1 US 45189706 A US45189706 A US 45189706A US 2006281712 A1 US2006281712 A1 US 2006281712A1
Authority
US
United States
Prior art keywords
compound
heterocycloalkyl
cycloalkyl
alkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/451,897
Other languages
English (en)
Inventor
Chi-Feng Yen
Cheng-Kung Hu
Ming-Chen Chou
Chen-Tso Tseng
Chien-Huang Wu
Ying-Huey Huang
Shu-Jen Chen
Chi-Hsin King
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TaiGen Biotechnology Co Ltd
Original Assignee
TaiGen Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TaiGen Biotechnology Co Ltd filed Critical TaiGen Biotechnology Co Ltd
Priority to US11/451,897 priority Critical patent/US20060281712A1/en
Publication of US20060281712A1 publication Critical patent/US20060281712A1/en
Assigned to TAIGEN BIOTECHNOLOGY reassignment TAIGEN BIOTECHNOLOGY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHEN, SHU-JEN, CHOU, MING-CHEN, HU, CHENG-KUNG, HUANG, YING-HUEY, KING, CHI-HSIN RICHARD, TSENG, CHEN-TSO, WU, CHIEN-HUANG, YEN, CHI-FENG
Priority to US12/330,132 priority patent/US8193206B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • Chemokines are a family of cytokines that regulate the adhesion and transendothelial migration of leukocytes during an immune or inflammatory reaction (Mackay C. R., Nat. Immunol., (2001) 2:95; Olson et al., Am. J. Physiol. Regul. Integr. Comp. Physiol., (2002) 283:R7). Chemokines also regulate T cells and B cells trafficking and homing, and contribute to the development of lymphopoietic and hematopoietic systems (Ajuebor et al., Biochem. Pharmacol., (2002) 63:1191). Approximately 50 chemokines have been identified in humans.
  • CXC CX3C
  • CC C chemokines
  • the biological functions of chemokines are mediated by their binding and activation of G protein-coupled receptors (GPCRs) on the cell surface.
  • GPCRs G protein-coupled receptors
  • CXCR4 receptor for example, it can be activated by Stromal-derived factor-1 or SDF-1, a member of CXC chemokines.
  • SDF-1 was originally cloned from bone marrow stromal cell lines and found to act as a growth factor for progenitor B cells (Nishikawa et al., Eur. J. Immunol., (1988) 18:1767). SDF-1 also induces bone marrow colonization of hematopoietic precursor cells during embryogenesis (Bleul et al., J. Exp. Med., (1996) 184:1101). The physiological function of SDF-1 is mediated by CXCR4 receptor.
  • mice lacking SDF-1 or CXCR4 receptor show lethal abnormality in bone marrow myelopoiesis, B cell lymphopoiesis, and cerebellar development (Nagasawa et al., Nature, (1996) 382:635; Ma et al., Proc. Natl. Acad. Sci., (1998) 95:9448; Zou et al., Nature (1998) 393:595; Lu et al., Proc. Natl. Acad. Sci. (2002) 99:7090).
  • CXCR4 receptor is expressed broadly in a variety of tissues, particularly in immune and central nervous systems, and has been described as the major co-receptor for HIV-1/2 on T lymphocytes.
  • CXCR4 receptor and SDF-1 are also involved in other pathological conditions such as rheumatoid arthritis, asthma, and tumor metastases (Buckley et al., J. Immunol., (2000) 165:3423).
  • CXCR4 receptor and SDF-1 are also found widely expressed in many tissues during embryonic development.
  • the CXCR4/SDF-1 pathway has been shown to be critically involved in the regeneration of several tissue injury models. Specifically, it has been found that the SDF-1 level is elevated at an injured site and CXCR4-positive cells actively participate in the tissue regenerating process.
  • This invention is based on the discovery that certain pyrimidine compounds are effective in treating inflammatory and immune diseases (e.g., retinopathy), developmental or degenerative diseases, or tissue injuries through their binding to chemokine receptors (e.g., CXCR3 or CXCR4 receptors).
  • chemokine receptors e.g., CXCR3 or CXCR4 receptors.
  • these compounds when used in combination with G-CSF growth factor, exhibited synergistic effects in stem cells and endothelial progenitor cells mobilization.
  • this invention features pyrimidine compounds of formula (I) and their salts:
  • X is —N(R a )— or —O—; or X, together with R 5 , is C 3 -C 20 heterocycloalkyl; or X, together with L 2 and L 3 , is C 3 -C 20 heterocycloalkyl; each of L 1 and L 2 , independently, is C 1 -C 10 alkylene, C 1 -C 10 heteroalkylene, —C(O)—, or deleted; or L 1 , together with L 3 , R 4 , and the nitrogen attached to R 4 , is C 3 -C 20 heterocycloalkyl, or L 2 , together with L 3 and X, is C 3 -C 20 heterocycloalkyl; L 3 is —N(R b )—, —O—, aryl, heteroaryl, or C 3 -C 20 cycloalkyl; or L 3 , together with L 1
  • pyrimidine compounds described above are those in which X can be —N(R a )—, each of L 1 and L 2 , independently, can be C 1 -C 10 alkylene, —C(O)—, or deleted; and L 3 can be —N(R b )—, —O—, aryl, or C 3 -C 20 cycloalkyl.
  • L 3 is —N(R b )—.
  • R 5 can be C 3 -C 20 cycloalkyl (e.g., ) C 1 -C 10 alkyl substituted with C 3 -C 20 cycloalkyl (e.g., ), or C 3 -C 20 heterocycloalkyl substituted with C 1 -C 10 alkyl (e.g., );
  • R b can be C 1 -C 10 alkyl substituted with N(R′R′′), in which each of R′ and R′′, independently, is H, C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, or heteroaryl; and R 1 can be C 3 -C 20 heterocycloalkyl (e.g., ).
  • L 3 can be aryl (e.g., phenylene).
  • R 5 can be C 1 -C 10 alkyl substituted with C 3 -C 20 heterocycloalkyl (e.g., ) or C 1 -C 10 alkyl substituted with N(R e R f ) (e.g., ); R 5 , together with X, is C 3 -C 20 heterocycloalkyl (e.g., ).
  • R 3 can be H, halo C 1 -C 10 alkyl, OR c , NR c R d , or C 3 -C 20 heterocycloalkyl optionally substituted with C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, OR′, C(O)R′, COOR′, C(O)N(R′R′′), SO 2 R′, C(S)N(R′R′′), OSO 3 R′, or PO(OR′) 2 , in which each of R′ and R′′, independently, is H, C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, or heteroaryl.
  • R 3 can be H, Cl, CH 3 , OPh, optionally substituted with OH, optionally substituted with C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, OH, C(O)R′, COOR′, C(O)N(R′R′′), SO 2 R′, C(S)N(R′R′′), OSO 3 R′, PO(OR′) 2 , or NH(R′) substituted with OH or NHC(O)R′′.
  • L 3 can be C 3 -C 20 cycloalkyl (e.g., cyclohexylene).
  • R 5 can be C 1 -C 10 alkyl substituted with N(R e R f ) (e.g., ) and R 3 can be C 3 -C 20 heterocycloalkyl substituted with C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, OR′, C(O)R′, COOR′, C(O)N(R′R′′), SO 2 R′, or C(S)N(R′R′′), in which each of R′ and R′′, independently, is H, C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, or heteroaryl.
  • alkyl refers to a saturated or unsaturated, linear or branched hydrocarbon moiety, such as —CH 3 , —CH 2 —CH ⁇ CH 2 , or branched —C 3 H 7 .
  • alkylene refers to a divalent, saturated or unsaturated, linear or branched hydrocarbon moiety, such as —CH 2 — or —CH ⁇ CH—.
  • heteroalkylene refers to an alkylene moiety having at least one heteroatom (e.g., N, O, or S).
  • cycloalkyl refers to a saturated or unsaturated, non-aromatic, cyclic hydrocarbon moiety, such as cyclohexyl or cyclohexen-3-yl.
  • heterocycloalkyl refers to a saturated or unsaturated, non-aromatic, cyclic moiety having at least one ring heteroatom (e.g., N, O, or S), such as 4-tetrahydropyranyl or 4-pyranyl.
  • aryl refers to a hydrocarbon moiety having one or more aromatic rings.
  • aryl moieties include phenyl (Ph), phenylene, naphthyl, naphthylene, pyrenyl, anthryl, and phenanthryl.
  • heteroaryl refers to a moiety having one or more aromatic rings that contain at least one heteroatom (e.g., N, O, or S).
  • heteroaryl moieties include furyl, furylene, fluorenyl, pyrrolyl, thienyl, oxazolyl, imidazolyl, thiazolyl, pyridyl, pyrimidinyl, quinazolinyl, quinolyl, isoquinolyl and indolyl.
  • Alkyl, alkylene, heteroalkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl mentioned herein include both substituted and unsubstituted moieties, unless specified otherwise.
  • Possible substituents on cycloalkyl, heterocycloalkyl, aryl, and heteroaryl include, but are not limited to, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 20 cycloalkyl, C 3 -C 20 cycloalkenyl, C 3 -C 20 heterocycloalkyl, C 3 -C 20 heterocycloalkenyl, C 1 -C 10 alkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, amino, C 1 -C 10 alkylamino, C 1 -C 20 dialkylamino, arylamino, diarylamino, hydroxyl, halogen
  • alkyl, alkylene, or heteroalkylene include all of the above-recited substituents except C 1 -C 10 alkyl, C 2 -C 10 alkenyl, and C 2 -C 10 alkynyl. Cycloalkyl, heterocycloalkyl, aryl, and heteroaryl can also be fused with each other.
  • this invention features pyrimidine compounds of formula (I) shown above in which X is —N(R a )— or —O—; each of L 1 and L 2 , independently, is C 1 -C 10 alkylene, C 1 -C 10 heteroalkylene, —C(O)—, or deleted; L 3 is —N(R b )—, C 3 -C 20 cycloalkyl, aryl, heteroaryl, or deleted; R 1 is H, C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, aryl, heteroaryl, halo, CN, OR c , COOR c , OC(O)R c , C(O)R c , C(O)NR c R d , or NR c R d ; each of R 2 and R 3 , independently, is H, C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C
  • pyrimidine compounds are those in which X is —N(R a )—; each of L 1 and L 2 , independently, is C 1 -C 10 alkylene; L 3 is deleted; R 1 is NR c R d ; each of R 2 and R 3 , independently, is H, C 1 -C 10 alkyl, halo, or C 3 -C 20 cycloalkyl; and each of R 4 and R 5 , independently, is H or C 3 -C 20 cycloalkyl; or R 4 and R 5 together are C 1 -C 10 alkylene or C 1 -C 10 heteroalkylene.
  • R 5 can be or R 4 and R 5 together can be —CH 2 CH 2 —; one of R c and R d can be C 1 -C 10 alkyl substituted with N(RR′) or aryl, in which each of R and R′, independently, is H, C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, or heteroaryl (e.g., one of R c and R d being R 3 can be substituted with C 1 -C 10 alkyl, which is in turn substituted with C 3 -C 20 heterocycloalkyl or OR, R being H, C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, or heteroaryl.
  • this invention features a method for treating an inflammatory or immune disease, a developmental or degenerative disease, or a tissue injury.
  • the method includes administering to a subject in need thereof an effective amount of one or more pyrimidine compounds of formula (I) shown above.
  • treating refers to administering one or more pyrimidine compounds to a subject, who has an above-described disease, a symptom of such a disease, or a predisposition toward such a disease, with the purpose to confer a therapeutic effect, e.g., to cure, relieve, alter, affect, ameliorate, or prevent the above-described disease, the symptom of it, or the predisposition toward it.
  • An inflammatory disease is characterized by a local or systemic, acute or chronic inflammation.
  • retinopathy inflammatory dermatoses (e.g., dermatitis, eczema, atopic dermatitis, allergic contact dermatitis, urticaria, necrotizing vasculitis, cutaneous vasculitis, hypersensitivity vasculitis, eosinophilic myositis, polymyositis, dermatomyositis, and eosinophilic fasciitis), inflammatory bowel diseases (e.g., Crohn's disease and ulcerative colitis), hypersensitivity lung diseases (e.g., hypersensitivity pneumonitis, eosinophilic pneumonia, delayed-type hypersensitivity, interstitial lung disease or ILD, idiopathic pulmonary fibrosis, and ILD associated with rheumatoid arthritis), asthma, and allergic rhinitis.
  • inflammatory dermatoses e.g., dermatitis, e
  • An immune disease is characterized by a hyper- or hypo-reaction of the immune system.
  • autoimmune diseases e.g., rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, myasthenia gravis, juvenile onset diabetes, glomerulonephritis, autoimmune throiditis, ankylosing spondylitis, systemic sclerosis, and multiple sclerosis
  • acute and chronic inflammatory diseases e.g., systemic anaphylaxia or hypersensitivity responses, drug allergies, insect sting allergies, graft rejection, including allograft rejection, and graft-versus-host disease
  • Sjogren's syndrome human immunodeficiency virus infection, cancer (e.g., brain, breast, prostate, colon, kidney, ovary, thyroid, lung, and haematopoietic cancer), and tumor metastasis.
  • Degenerative diseases are growth or differentiation related disorders that lead to loss-of-function or gain-of-function.
  • Degenerative diseases generally refer to change of a tissue to a lower or less functional form.
  • Examples of a developmental or degenerative disease include spinal muscular atrophy, Duchenne muscular dystrophy, Parkinson's disease, and Alzheimer's disease.
  • Tissue injuries can be caused by oxidative stress (e.g., ischemia-reperfusion in stroke or myocardial infarction), complement activation, graft rejection, chemicals (e.g., alcohol-induced liver damage or mucosal tissue injuries in cancer therapy), viral infection (e.g., glomerular injuries associated with hepatitis C infection), and mechanical forces (e.g., sports injury).
  • tissue injuries include brain injury, heart injury, liver damage, skeletal muscle injury, kidney damage, pancreatic injury, lung injury, skin injury, and gastrointestinal tract injury.
  • a subject in need of treatment of an above-described disease can also be concurrently administered with a pyrimidine compound described above and one or more other therapeutic agents.
  • a therapeutic agent include a G-CSF growth factor, a steroidal or a non-steroidal anti-inflammatory drug, a COX2 inhibitor, a leukotriene receptor inhibitor, a prostaglandin modulator, a TNF modulator, and an immunosuppressive agent (e.g., cyclosporine A).
  • the term “concurrently administered” refers to administering a pyrimidine compound and one or more other therapeutic agents at the same time or at different times during the period of treatment.
  • this invention features a method for enhancing migration of bone marrow-derived cells to blood.
  • the method includes administering to a subject in need thereof an effective amount of one or more pyrimidine compounds of formula (I) shown above.
  • bone marrow-derived cells refers to cells originating from bone marrow. Examples of bone marrow-derived cells include, but are not limited to, CD34+ cells and CD133+ cells. Preferrably, bone marrow-derived cells are stem cells or endothelial progenitor cells.
  • this invention features a chemical synthetic method.
  • the method includes reacting a compound of the formula with a compound of the formula to give a compound of formula (II):
  • A is phenylene, cyclohexylene, each of R 1 , R 2 , and R 3 , independently, is H, C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, heteroaryl, halo, CN, OR a , COOR a , OC(O)R a , C(O)R a , C(O)NR a R b , or NR a R b ;
  • R 6 is halo;
  • R 7 is a amino-protecting group (e.g., t-butoxycarbonyl, benzyloxycarbonyl, acetyl, phenylcarbonyl, or trialkylsilyl); in which each of R
  • the method can further include deprotecting the compound of formula (II) to give a compound of formula (III): (III).
  • R 1 is N(R a R b ), in which R a and R b , independently, is H, C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, or heteroaryl.
  • R a and R b can be
  • R 3 is optionally substituted with C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, or aryl.
  • a compound of formula (II) when R 3 is halo, a compound of formula (II) can further react with a compound of the formula to give a compound of formula (IV): (IV).
  • Y is —O—, —CH 2 —, or —N(R c )—, in which R c is H, C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, heteroaryl, or halo.
  • the compound of formula (IV) can be deprotected to give a compound of formula (V): Referring to formula (IV), when Y is NH, a compound of formula (IV) can further react with a compound of the formula to give a compound of formula (VI): (VI), in which Z is —CH 2 — or —C(O)—; R d is C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, or heteroaryl; and R c is halo.
  • the compound of formula (VI) can be deprotected to give a compound of formula (VII): (VII).
  • a compound of formula (IV) can further react with a compound of the formula to give an imine compound, followed by reducing the imine compound to give a compound of formula (VI).
  • Z is —C(O)—;
  • R d is C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, or heteroaryl; and
  • R e is H.
  • a compound of formula (IV) can further react with a compound of the formula to give an ester compound, followed by hydrolyzing the ester compound to give a compound of formula (VIII): (VIII), in which R d is C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, or heteroaryl.
  • R d is C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, or heteroaryl.
  • the compound of formula (VIII) can be deprotected to give a compound of formula (IX): (IX).
  • a compound of formula (IV) can further react with a compound of the formula to give a compound of formula (X): (X), in which R d is C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, or heteroaryl.
  • the compound of formula (X) can be deprotected to give a deprotected compound, followed by hydrolyzing the deprotected compound to give a compound of formula (XI):
  • a compound of formula (II) when R 3 is halo, a compound of formula (II) can further react with a compound of the formula R c OH to give a compound of formula (XII): (XII), in which R c is C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, or heteroaryl.
  • R c is C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, or heteroaryl.
  • the compound of formula (XII) can be deprotected to give a compound of formula (XIII):
  • the compound of formula (II) when R 2 is CN, the compound of formula (II) can be reduced to give a compound of formula (XIV): (XIV).
  • the compound of formula (XIV) can further react with a compound of the formula R c NH 2 to give an imine compound, followed by reducing the imine compound to give a compound of formula (XV): (XV), in which R c is C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, or heteroaryl.
  • R c is C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, or heteroaryl.
  • the compound of formula (XV) can be deprotected to give a compound of formula (XVI):
  • the invention features a chemical synthetic method that includes reacting a compound of the formula with a compound of the formula to give a compound of formula (XVII): (XVII).
  • each of R 1 and R 2 independently, is H, C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, heteroaryl, halo, CN, OR a , COOR a , OC(O)R a , C(O)R a , C(O)NR a R b , or NR a R b ; R 3 is halo; and R 6 is a amino-protecting group; in which each of R a and R b , independently, is 5H, C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, heteroaryl,
  • the method can further include protecting the compound of formula (XX), followed by reacting the protected compound of formula (XVII) with a compound of the formula to give a compound of formula (XVIII): (XVIII).
  • R 7 is a amino-protecting group
  • Y is —O—, —CH 2 —, or —N(R c )—, in which R c is H, C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, heteroaryl, or halo.
  • the method can further include: (1) reacting the compound of formula (XVIII) with a compound of the formula to give an ester compound; (2) hydrolyzing the ester compound to give an acid compound; and (3) deprotecting the acid compound to give a compound of formula (XIX): (XIX), in which R d is C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, or heteroaryl; and R e is halo.
  • this invention encompasses a pharmaceutical composition that contains an effective amount of at least one of the above-mentioned pyrimidine compounds and a pharmaceutically acceptable carrier.
  • the pyrimidine compounds described above include the compounds themselves, as well as their salts, prodrugs, and solvates, if applicable.
  • a salt for example, can be formed between an anion and a positively charged group (e.g., amino) on a pyrimidine compound.
  • Suitable anions include chloride, bromide, iodide, sulfate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, acetate, malate, tosylate, tartrate, fumurate, glutamate, glucuronate, lactate, glutarate, and maleate.
  • a salt can also be formed between a cation and a negatively charged group (e.g., carboxylate) on a pyrimidine compound.
  • Suitable cations include sodium ion, potassium ion, magnesium ion, calcium ion, and an ammonium cation such as tetramethylammonium ion.
  • the pyrimidine compounds also include those salts containing quaternary nitrogen atoms.
  • prodrugs include esters and other pharmaceutically acceptable derivatives, which, upon administration to a subject, are capable of providing active pyrimidine compounds.
  • a solvate refers to a complex formed between an active pyrimidine compound and a pharmaceutically acceptable solvent.
  • pharmaceutically acceptable solvents include water, ethanol, isopropanol, ethyl acetate, acetic acid, and ethanolamine.
  • compositions containing one or more of the pyrimidine compounds described above for use in treating an above-described disease, and the use of such a composition for the manufacture of a medicament for the just-mentioned treatment.
  • pyrimidine compounds described above can be prepared by methods well known in the art. Examples 1-268 below provide detailed descriptions of the preparation of compounds 1-268 of this invention.
  • Scheme I shown below depicts a typical synthetic route for synthesizing certain exemplary compounds.
  • R 1 , R 2 , R 3 , R 6 , and R 7 are as defined in the Summary section above.
  • a pyrimidine compound containing a halo group reacts with a compound containing two protected amino groups and an unprotected primary amino group to give a compound of formula (2), which is subsequently deprotected by removing the amino-protecting group to give a compound of formula (3).
  • Exemplary amino-protecting groups include t-butoxycarbonyl, benzyloxycarbonyl, acetyl, phenylcarbonyl, and trialkylsilyl.
  • a compound of formula (2) can be first reduced to give a compound of formula (10), which contains an aldehyde group.
  • the compound of formula (10) can then react with a primary amine to give a compound of formula (11), which can be subsequently deprotected to form a compound of formula (12).
  • a pyrimidine compound thus synthesized can be purified by a method such as column chromatography, high-pressure liquid chromatography, or recrystallization.
  • pyrimidine compounds can be prepared using other suitable starting materials through the above synthetic routes and others known in the art.
  • the methods described above may also additionally include steps, either before or after the steps described specifically herein, to add or remove suitable protecting groups in order to ultimately allow synthesis of the pyrimidine compounds.
  • various synthetic steps may be performed in an alternate sequence or order to give the desired compounds.
  • Synthetic chemistry transformations and protecting group methodologies useful in synthesizing applicable pyrimidine compounds are known in the art and include, for example, those described in R. Larock, Comprehensive Organic Transformations , VCH Publishers (1989); T. W. Greene and P. G. M.
  • the pyrimidine compounds mentioned herein may contain a non-aromatic double bond and one or more asymmetric centers. Thus, they can occur as racemates and racemic mixtures, single enantiomers, individual diastereomers, diastereomeric mixtures, and cis- or trans-isomeric forms. All such isomeric forms are contemplated.
  • a pharmaceutical composition containing an effective amount of at least one pyrimidine compound described above and a pharmaceutical acceptable carrier. Further, this invention covers a method of administering an effective amount of one or more of the pyrimidine compounds to a patient having a disease described in the summary section above. This invention also covers a method of administering an effective amount of one or more of the pyrimidine compounds for enhancing migration of bone marrow-derived cells to blood. “An effective amount” refers to the amount of an active pyrimidine compound that is required to confer a therapeutic effect on the treated subject. Effective doses will vary, as recognized by those skilled in the art, depending on the types of diseases treated, route of administration, excipient usage, and the possibility of co-usage with other therapeutic treatment.
  • a composition having one or more pyrimidine compounds can be administered parenterally, orally, nasally, rectally, topically, or buccally.
  • parenteral refers to subcutaneous, intracutaneous, intravenous, intrmuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional, or intracranial injection, as well as any suitable infusion technique.
  • a sterile injectable composition can be a solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butanediol.
  • a non-toxic parenterally acceptable diluent or solvent such as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that can be employed are mannitol, water, Ringer's solution, and isotonic sodium chloride solution.
  • fixed oils are conventionally employed as a solvent or suspending medium (e.g., synthetic mono- or diglycerides).
  • Fatty acid, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • oil solutions or suspensions can also contain a long chain alcohol diluent or dispersant, carboxymethyl cellulose, or similar dispersing agents.
  • a long chain alcohol diluent or dispersant carboxymethyl cellulose, or similar dispersing agents.
  • Other commonly used surfactants such as Tweens or Spans or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms can also be used for the purpose of formulation.
  • a composition for oral administration can be any orally acceptable dosage form including capsules, tablets, emulsions and aqueous suspensions, dispersions, and solutions.
  • commonly used carriers include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried corn starch.
  • a nasal aerosol or inhalation composition can be prepared according to techniques well known in the art of pharmaceutical formulation.
  • such a composition can be prepared as a solution in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.
  • composition having one or more active pyrimidine compounds can also be administered in the form of suppositories for rectal administration.
  • the carrier in the pharmaceutical composition must be “acceptable” in the sense that it is compatible with the active ingredient of the composition (and preferably, capable of stabilizing the active ingredient) and not deleterious to the subject to be treated.
  • One or more solubilizing agents can be utilized as pharmaceutical excipients for delivery of an active pyrimidine compound.
  • examples of other carriers include colloidal silicon oxide, magnesium stearate, cellulose, sodium lauryl sulfate, and D&C Yellow # 10.
  • pyrimidine compounds described above can be preliminarily screened for their efficacy in treating above-described diseases by an in vitro assay (See Examples 269 and 270 below) and then confirmed by animal experiments and clinic trials. Other methods will also be apparent to those of ordinary skill in the art.
  • Compound 4 was prepared in a manner similar to that used to prepare compound 1.
  • Compound 7 was prepared in a manner similar to that used to prepare compound 1.
  • N-cyclohexyl-1,3-propanediamine (0.808 g) was slowly added to a stirred solution of 2,4,6-trichloropyrimidine (1 g) in THF (50 mL) at room temperature.
  • the reaction mixture was stirred at 0° C. for 2 hours and the reaction was allowed to warm-up to room temperature overnight.
  • N-cyclohexyl-1,3-propanediamine (0.808 g) was slowly added to a stirred solution of 2,4,6-trichloropyrimidine (1 g) in THF (50 mL) at room temperature.
  • the reaction mixture was stirred at 0° C. for 2 hours and the reaction was allowed to warm-up to room temperature overnight.
  • Compound 12 was prepared in a manner similar to that used to prepare compound 8.
  • Compound 13 was prepared in a manner similar to that used to prepare compound 10.
  • Compound 14 was prepared in a manner similar to that used to prepare compound 8.
  • Compound 15 was prepared in a manner similar to that used to prepare compound 8.
  • Compound 16 was prepared in a manner similar to that used to prepare compound 8.
  • Compound 17 was prepared in a manner similar to that used to prepare compound 11.
  • Compound 18 was prepared in a manner similar to that used to prepare compound 10.
  • Compound 19 was prepared in a manner similar to that used to prepare compound 11.
  • Compound 22 was prepared in a manner similar to that used to prepare compound 21.
  • Compound 23 was prepared in a manner similar to that used to prepare compound 21.
  • Compound 24 was prepared in a manner similar to that used to prepare compound 10.
  • Compound 25 was prepared in a manner similar to that used to prepare compound 11.
  • Compound 26 was prepared in a manner similar to that used to prepare compound 8.
  • Compound 27 was prepared in a manner similar to that used to prepare compound 21.
  • Compound 28 was prepared in a manner similar to that used to prepare compound 21.
  • Compound 30 was prepared in a manner similar to that used to prepare compound 29.
  • Compound 31 was prepared in a manner similar to that used to prepare compound 21.
  • Compound 32 was prepared in a manner similar to that used to prepare compound 21.
  • Intermediate 34-I was obtained as an intermediate during the preparation of compound 21.
  • Compound 36 was prepared in a manner similar to that used to prepare compound 35.
  • Compound 37 was prepared in a manner similar to that used to prepare compound 21.
  • Compound 38 was prepared in a manner similar to that used to prepare compound 21.
  • Compound 39 was prepared in a manner similar to that used to prepare compound 21.
  • Compound 40 was prepared in a manner similar to that used to prepare compound 21.
  • Compound 41 was prepared in a manner similar to that used to prepare compound 33.
  • Compound 42 was prepared in a manner similar to that used to prepare compound 33.
  • Compound 45 was prepared in a manner similar to that used to prepare compound 43.
  • Compound 46 was prepared in a manner similar to that used to prepare compound 43.
  • Compound 47 was prepared in a manner similar to that used to prepare compound 21.
  • Compound 48 was prepared in a manner similar to that used to prepare compound 21.
  • Compound 49 was prepared in a manner similar to that used to prepare compound 21.
  • Compound 50 was prepared in a manner similar to that used to prepare compound 43.
  • Compound 51 was prepared in a manner similar to that used to prepare compound 43.
  • Compound 52 was prepared in a manner similar to that used to prepare compound 43.
  • Compound 53 was prepared in a manner similar to that used to prepare compound 44.
  • Compound 54 was prepared in a manner similar to that used to prepare compound 44.
  • Compound 55 was prepared in a manner similar to that used to prepare compound 44.
  • Compound 56 was prepared in a manner similar to that used to prepare compound 44.
  • Compound 57 was prepared in a manner similar to that used to prepare compound 44.
  • Compound 58 was prepared in a manner similar to that used to prepare compound 44.
  • Compound 60 was prepared in a manner similar to that used to prepare compound 44.
  • Compound 61 was prepared in a manner similar to that used to prepare compound 44.
  • Compound 63 was prepared in a manner similar to that used to prepare compound 44.
  • Compound 64 was prepared in a manner similar to that used to prepare compound 44.
  • Compound 65 was prepared in a manner similar to that used to prepare compound 21.
  • Compound 66 was prepared in a manner similar to that used to prepare compound 21.
  • Compound 67 was prepared in a manner similar to that used to prepare compound 21.
  • Compound 68 was prepared in a manner similar to that used to prepare compound 21.
  • Compound 69 was prepared in a manner similar to that used to prepare compound 21.
  • Compound 71 was prepared in a manner similar to that used to prepare compound 21.
  • Compound 72 was prepared in a manner similar to that used to prepare compound 21.
  • Compound 73 was prepared in a manner similar to that used to prepare compound 21.
  • Compound 74 was prepared in a manner similar to that used to prepare compound 35.
  • Compound 75 was prepared in a manner similar to that used to prepare compound 35.
  • Compound 76 was prepared in a manner similar to that used to prepare compound 44.
  • Compound 77 was prepared in a manner similar to that used to prepare compound 44.
  • Compound 78 was prepared in a manner similar to that used to prepare compound 44.
  • Compound 79 was prepared in a manner similar to that used to prepare compound 70.
  • Compound 80 was prepared in a manner similar to that used to prepare compound 33.
  • Compound 81 was prepared in a manner similar to that used to prepare compound 33.
  • Compound 82 was prepared in a manner similar to that used to prepare compound 33.
  • Compound 83 was prepared in a manner similar to that used to prepare compound 33.
  • Compound 84 was prepared in a manner similar to that used to prepare compound 44.
  • Compound 85 was prepared in a manner similar to that used to prepare compound 44.
  • Compound 86 was prepared in a manner similar to that used to prepare compound 70.
  • Compound 87 was prepared in a manner similar to that used to prepare compound 35.
  • Compound 88 was prepared in a manner similar to that used to prepare compound 35.
  • Compound 90 was prepared in a manner similar to that used to prepare compound 44.
  • Compound 91 was prepared in a manner similar to that used to prepare compound 44.
  • Compound 92 was prepared in a manner similar to that used to prepare compound 34.
  • Compound 93 was prepared in a manner similar to that used to prepare compound 34.
  • Compound 94 was prepared in a manner similar to that used to prepare compound 33.
  • Compound 96 was prepared in a manner similar to that used to prepare compound 43.
  • Compound 97 was prepared in a manner similar to that used to prepare compound 43.
  • Compound 98 was prepared in a manner similar to that used to prepare compound 43.
  • Compound 99 was prepared in a manner similar to that used to prepare compound 43.
  • Compound 100 was prepared in a manner similar to that used to prepare compound 43.
  • Compound 101 was prepared in a manner similar to that used to prepare compound 43.
  • Compound 102 was prepared in a manner similar to that used to prepare compound 43.
  • Compound 103 was prepared in a manner similar to that used to prepare compound 44.
  • Compound 104 was prepared in a manner similar to that used to prepare compound 44.
  • Compound 105 was prepared in a manner similar to that used to prepare compound 44.
  • Compound 106 was prepared in a manner similar to that used to prepare compound 33.
  • Compound 107 was prepared in a manner similar to that used to prepare compound 44.
  • Compound 108 was prepared in a manner similar to that used to prepare compound 44.
  • Compound 110 was prepared in a manner similar to that used to prepare compound 70.
  • Compound 111 was prepared in a manner similar to that used to prepare compound 70.
  • Compound 112 was prepared in a manner similar to that used to prepare compound 44.
  • Compound 113 was prepared in a manner similar to that used to prepare compound 33.
  • Compound 115 was prepared in a manner similar to that used to prepare compound 44.
  • Compound 118 was prepared in a manner similar to that used to prepare compound 117.
  • Compound 119 was prepared in a manner similar to that used to prepare compound 116.
  • Compound 120 was prepared in a manner similar to that used to prepare compound 117.
  • Compound 122 was prepared in a manner similar to that used to prepare compound 62.
  • Compound 123 was prepared in a manner similar to that used to prepare compound 62.
  • Compound 124 was prepared in a manner similar to that used to prepare compound 117.
  • Compound 125 was prepared in a manner similar to that used to prepare compound 117.
  • Compound 126 was prepared in a manner similar to that used to prepare compound 116.
  • Compound 127 was prepared in a manner similar to that used to prepare compound 116.
  • Compound 128 was prepared in a manner similar to that used to prepare compound 43.
  • Compound 129 was prepared in a manner similar to that used to prepare compound 43.
  • Compound 130 was prepared in a manner similar to that used to prepare compound 43.
  • Compound 131 was prepared in a manner similar to that used to prepare compound 43.
  • Compound 132 was prepared in a manner similar to that used to prepare compound 43.
  • Compound 133 was prepared in a manner similar to that used to prepare compound 43.
  • Compound 134 was prepared in a manner similar to that used to prepare compound 43.
  • Compound 135 was prepared in a manner similar to that used to prepare compound 109.
  • Compound 136 was prepared in a manner similar to that used to prepare compound 109.
  • Compound 137 was prepared in a manner similar to that used to prepare compound 21.
  • Compound 138 was prepared in a manner similar to that used to prepare compound 21.
  • Compound 139 was prepared in a manner similar to that used to prepare compound 21.
  • Compound 140 was prepared in a manner similar to that used to prepare compound 21.
  • Compound 141 was prepared in a manner similar to that used to prepare compound 44.
  • Compound 143 was prepared in a manner similar to that used to prepare compound 142.
  • Compound 145 was prepared in the same manner as that used to prepare intermediate 144-II.
  • Compound 146 was prepared in a manner similar to that used to prepare compound 144.
  • Compound 147 was prepared in a manner similar to that used to prepare compound 44.
  • Compound 148 was prepared in a manner similar to that used to prepare compound 44.
  • Compound 149 was prepared in a manner similar to that used to prepare compound 116.
  • Compound 150 was prepared in a manner similar to that used to prepare compound 116.
  • Compound 151 was prepared in a manner similar to that used to prepare compound 116.
  • Compound 152 was prepared in a manner similar to that used to prepare compound 116.
  • Compound 153 was prepared in a manner similar to that used to prepare compound 116.
  • Compound 154 was prepared from compound 62-III in a manner similar to that used to prepare compound 144.
  • Compound 155 was prepared from compound 62-III in a manner similar to that used to prepare compound 144.
  • Compound 156 was prepared from compound 62-III in a manner similar to that used to prepare compound 144.
  • Compound 157 was prepared from compound 109-I in a manner similar to that used to prepare compound 109.
  • Compound 158 was prepared from compound 109-I in a manner similar to that used to prepare compound 109.
  • Compound 159 was prepared from compound 109-I in a manner similar to that used to prepare compound 109.
  • Compound 160 was prepared from compound 109-I in a manner similar to that used to prepare compound 109.
  • Compound 161 was prepared from compound 21-II in a manner similar to that used to prepare compound 154.
  • Compound 162 was prepared from compound 21-II in a manner similar to that used to prepare compound 154.
  • Compound 163 was prepared from compound 21-II in a manner similar to that used to prepare compound 154.
  • Compound 164 was prepared from compound 21-II in a manner similar to that used to prepare compound 154.
  • Compound 165 was prepared from compound 21-II in a manner similar to that used to prepare compound 154.
  • Compound 166 was prepared in a manner similar to that used to prepare compound 43.
  • Compound 167 was prepared in a manner similar to that used to prepare compound 43.
  • Compound 168 was prepared in a manner similar to that used to prepare compound 109.
  • Compound 169 was prepared from compound 34-I in a manner similar to that used to prepare compound 34.
  • Compound 170 was prepared from compound 34-I in a manner similar to that used to prepare compound 34.
  • Compound 171 was prepared from compound 70-I and the corresponding thioisocyanate in a manner similar to that used to prepare compound 70.
  • Compound 172 was prepared from compound 70-I and the corresponding thioisocyanate in a manner similar to that used to prepare compound 70.
  • Compound 173 was prepared from compound 70-I and the corresponding thioisocyanate in a manner similar to that used to prepare compound 70.
  • Compound 174 was prepared from compound 70-I and the corresponding thioisocyanate in a manner similar to that used to prepare compound 70.
  • Compound 175 was prepared from compound 70-I and the corresponding thioisocyanate in a manner similar to that used to prepare compound 70.
  • Compound 176 was prepared from compound 70-I and the corresponding thioisocyanate in a manner similar to that used to prepare compound 70.
  • Compound 177 was prepared from compound 70-I and the corresponding thioisocyanate in a manner similar to that used to prepare compound 70.
  • Compound 178 was prepared from compound 70-I and the corresponding thioisocyanate in a manner similar to that used to prepare compound 70.
  • Compound 179 was prepared from compound 70-I and the corresponding thioisocyanate in a manner similar to that used to prepare compound 70.
  • Compound 180 was prepared from compound 70-I and the corresponding thioisocyanate in a manner similar to that used to prepare compound 70.
  • Compound 181 was prepared from compound 70-I and the corresponding thioisocyanate in a manner similar to that used to prepare compound 70.
  • Compound 182 was prepared from compound 109-I in a manner similar to that used to prepare compound 109.
  • Compound 183 was prepared from compound 109-I in a manner similar to that used to prepare compound 109.
  • Compound 184 was prepared from compound 109-I in a manner similar to that used to prepare compound 109.
  • Compound 185 was prepared from compound 109-I in a manner similar to that used to prepare compound 109.
  • Compound 186 was prepared from compound 109-I in a manner similar to that used to prepare compound 109.
  • Compound 187 was prepared from compound 35-I in a manner similar to that used to prepare compound 35.
  • Compound 188 was prepared from compound 33-I in a manner similar to that used to prepare compound 33.
  • Compound 189 was prepared from compound 33-I in a manner similar to that used to prepare compound 33.
  • Compound 190 was prepared from compound 33-I in a manner similar to that used to prepare compound 33.
  • tert-Butoxycarbonylaminoethylamine (5.4 g) was added to a solution of 2,4-dichloro-6-methylpyrimidine (5 g) in THF (350 mL). The reaction mixture was stirred at 0° C. for 1 hour and then was allowed to warm-up to room temperature within 3 hours.
  • Compound 193 was prepared in a manner similar to that used to prepare compound 192.
  • Compound 194 was prepared in a manner similar to that used to prepare compound 192.
  • Compound 195 was prepared in a manner similar to that used to prepare compound 192.
  • Compound 196 was prepared in a manner similar to that used to prepare compound 192.
  • Compound 197 was prepared in a manner similar to that used to prepare compound 192.
  • Compound 199 was prepared in a manner similar to that used to prepare compound 197.
  • Compound 200 was prepared in a manner similar to that used to prepare compound 197.
  • Compound 202 was prepared in a manner similar to that used to prepare compound 200.
  • Compound 203 was prepared in a manner similar to that used to prepare compound 200.
  • Compound 205 was prepared in a manner similar to that used to prepare compound 204.
  • Compound 206 was prepared in a manner similar to that used to prepare compound 204.
  • Compound 207 was prepared in a manner similar to that used to prepare compound 204.
  • Compound 208 was prepared in a manner similar to that used to prepare compound 204.
  • Compound 209 was prepared in a manner similar to that used to prepare compound 204.
  • Compound 210 was prepared in a manner similar to that used to prepare compound 204.
  • Compound 211 was prepared in a manner similar to that used to prepare compound 204.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
US11/451,897 2005-06-14 2006-06-13 Pyrimidine compounds Abandoned US20060281712A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/451,897 US20060281712A1 (en) 2005-06-14 2006-06-13 Pyrimidine compounds
US12/330,132 US8193206B2 (en) 2005-06-14 2008-12-08 Pyrimidine compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69026705P 2005-06-14 2005-06-14
US79859606P 2006-05-08 2006-05-08
US11/451,897 US20060281712A1 (en) 2005-06-14 2006-06-13 Pyrimidine compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/330,132 Continuation-In-Part US8193206B2 (en) 2005-06-14 2008-12-08 Pyrimidine compounds

Publications (1)

Publication Number Publication Date
US20060281712A1 true US20060281712A1 (en) 2006-12-14

Family

ID=37571066

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/451,897 Abandoned US20060281712A1 (en) 2005-06-14 2006-06-13 Pyrimidine compounds
US11/451,771 Active 2027-05-30 US7589197B2 (en) 2005-06-14 2006-06-13 Pyrimidine compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/451,771 Active 2027-05-30 US7589197B2 (en) 2005-06-14 2006-06-13 Pyrimidine compounds

Country Status (11)

Country Link
US (2) US20060281712A1 (ja)
EP (1) EP1890703B1 (ja)
JP (1) JP5118029B2 (ja)
KR (1) KR101354114B1 (ja)
AU (1) AU2006259525B2 (ja)
CA (1) CA2612227C (ja)
EA (1) EA015890B1 (ja)
HK (1) HK1121062A1 (ja)
NZ (1) NZ564222A (ja)
TW (1) TWI376376B (ja)
WO (1) WO2006138304A2 (ja)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060293324A1 (en) * 2005-06-14 2006-12-28 Chi-Feng Yen Pyrimidine compounds
WO2007132846A1 (ja) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. 保護されていてもよい酸性基を含有する化合物およびその用途
WO2008016006A1 (en) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
FR2915747A1 (fr) * 2007-05-04 2008-11-07 Sod Conseils Rech Applic Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatase cdc25
US20090143302A1 (en) * 2005-06-14 2009-06-04 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
US20090264339A1 (en) * 2008-04-21 2009-10-22 Taigen Biotechnology Co., Ltd. Heterocyclic Compounds
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
WO2010020432A2 (en) * 2008-08-22 2010-02-25 Summit Corporation Plc Compounds for treatment of duchenne muscular dystrophy
US20100069368A1 (en) * 2007-03-15 2010-03-18 Miao Dai Organic Compounds and Their Uses
US20100120719A1 (en) * 2008-11-13 2010-05-13 Taigen Biotechnology Co., Ltd. Lyophilization formulation
US20100256373A1 (en) * 2006-03-31 2010-10-07 Edwards James P Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor
FR2945530A1 (fr) * 2009-05-15 2010-11-19 Ipsen Pharma Sas Derives de tri-amino-pyridine comme inhibiteurs de phosphatases cdc25
FR2945532A1 (fr) * 2009-05-15 2010-11-19 Ipsen Pharma Sas Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatases cdc25
WO2010130900A3 (fr) * 2009-05-15 2011-04-07 Ipsen Pharma S.A.S. Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatases cdc25
US20110230458A1 (en) * 2010-02-18 2011-09-22 Transtech Pharma, Inc. Phenyl-heteroaryl derivatives and methods of use thereof
EP2397482A1 (en) 2010-06-15 2011-12-21 Almirall, S.A. Heteroaryl imidazolone derivatives as jak inhibitors
EP2510926A1 (en) * 2009-12-08 2012-10-17 Institute of Radiation Medicine Academy of Military Medical Sciences of the Pla Use of saturated amines compounds in manufacture of medicaments for mobilizing peripheral blood hematopoietic stem cell
US8293757B2 (en) 2007-08-22 2012-10-23 Irm Llc 5-(4-(haloalkoxy)phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
US8859575B2 (en) 2013-03-06 2014-10-14 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
US9975886B1 (en) 2017-01-23 2018-05-22 Cadent Therapeutics, Inc. Potassium channel modulators
US10683293B2 (en) 2014-08-04 2020-06-16 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
US11447479B2 (en) 2019-12-20 2022-09-20 Nuevolution A/S Compounds active towards nuclear receptors
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors
US11780843B2 (en) 2020-03-31 2023-10-10 Nuevolution A/S Compounds active towards nuclear receptors
US11993586B2 (en) 2018-10-22 2024-05-28 Novartis Ag Crystalline forms of potassium channel modulators

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006307314C1 (en) 2005-10-25 2011-08-25 Shionogi & Co., Ltd. Aminodihydrothiazine derivative
BRPI0809715A2 (pt) 2007-04-16 2019-11-05 Hutchison Medipharma Entpr Ltd "composto, método de tratamento de um distúrbio relacionado com a angiogênese,método de inibição da atividade de receptor de domínio de inserto de quinase, método de inibição de angiogênese e método de tratamento de degeneração macular"
TW200902526A (en) 2007-04-24 2009-01-16 Shionogi & Amp Co Ltd Aminodihydrothiazin derivative substituted with a cyclic group
WO2008133273A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
EP2152702B1 (en) * 2007-05-04 2011-08-24 AstraZeneca AB Amino-thiazolyl- pyrimidine derivatives and their use for the treatment of cancer
US7829574B2 (en) 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
EP2299823A1 (en) 2008-05-19 2011-03-30 The University of Tennessee Research Foundation Pyrimidine non-classical cannabinoid compounds and related methods of use
US8389534B2 (en) 2008-05-19 2013-03-05 The University Of Tennessee Research Foundation Pyrimidine non-classical cannabinoid compounds and related methods of use
WO2009151098A1 (ja) 2008-06-13 2009-12-17 塩野義製薬株式会社 βセクレターゼ阻害作用を有する含硫黄複素環誘導体
CN102137857A (zh) 2008-06-30 2011-07-27 詹森药业有限公司 用于制备苯并咪唑-2-基嘧啶衍生物的方法
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
PT2310012E (pt) 2008-06-30 2015-04-02 Janssen Pharmaceutica Nv Processo para a preparação de derivados de pirimidina substituída
TW201008933A (en) 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
WO2010045377A2 (en) * 2008-10-14 2010-04-22 University Of Tennessee Research Foundation, The Pyrimidine non-classical cannabinoid compounds and related methods of use
WO2010047372A1 (ja) * 2008-10-22 2010-04-29 塩野義製薬株式会社 Ｂａｃｅ１阻害活性を有する２－アミノピリミジン－４－オンおよび２－アミノピリジン誘導体
US8999980B2 (en) 2009-12-11 2015-04-07 Shionogi & Co., Ltd. Oxazine derivatives
WO2011151360A1 (en) 2010-06-04 2011-12-08 F. Hoffmann-La Roche Ag Aminopyrimidine derivatives as lrrk2 modulators
JP5816630B2 (ja) 2010-10-29 2015-11-18 塩野義製薬株式会社 ナフチリジン誘導体
EP2634188A4 (en) 2010-10-29 2014-05-07 Shionogi & Co FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE
EP3590933B1 (en) 2010-11-10 2021-01-06 Genentech, Inc. Pyrazole aminopyrimidine derivatives as lrrk2 modulators
WO2012147763A1 (ja) 2011-04-26 2012-11-01 塩野義製薬株式会社 オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤
CN103204816B (zh) * 2012-01-16 2016-04-27 中国人民解放军军事医学科学院毒物药物研究所 哌嗪基嘧啶类衍生物及其制备方法和用途
WO2014065434A1 (en) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
US9708272B2 (en) 2014-08-29 2017-07-18 Tes Pharma S.R.L. Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase
US9375406B2 (en) * 2014-09-30 2016-06-28 Taigen Biotechnology Co., Ltd. Substituted pyrimidines for mobilizing cells expressing a type 4 CXC chemokine receptor
EP3568137A4 (en) 2017-01-10 2020-05-27 National Health Research Institutes HETEROCYCLIC COMPOUNDS AND USE OF SUCH COMPOUNDS
JP2022518016A (ja) 2019-01-18 2022-03-11 アストラゼネカ・アクチエボラーグ Ｐｃｓｋ９阻害剤及びその使用方法
KR102666918B1 (ko) * 2021-04-08 2024-05-20 주식회사 스탠다임 신규한 lrrk2 억제제
US20230085362A1 (en) * 2021-08-02 2023-03-16 National Health Research Institutes Pyrimidine compounds and use thereof
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034560A (en) * 1990-10-19 1991-07-23 The Standard Oil Company Synthesis of ethylamines
US6420354B1 (en) * 1998-06-08 2002-07-16 Advanced Medicine, Inc. Sodium channel drugs and uses
US20050124640A1 (en) * 2003-01-30 2005-06-09 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta
US20060293324A1 (en) * 2005-06-14 2006-12-28 Chi-Feng Yen Pyrimidine compounds
US7501412B2 (en) * 2002-11-22 2009-03-10 Mitsubishi Tanabe Pharma Corporation Isoquinoline compounds and medicinal use thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3759921A (en) * 1969-10-16 1973-09-18 Lilly Co Eli Method of suppressing immuneresponse with 1 substituted-3-(2 pyrimidyl)ureas
DE2853220A1 (de) * 1978-12-09 1980-07-03 Hoechst Ag Neue amino-pyrimidin-carbanilide, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
LU86960A1 (fr) * 1987-07-31 1989-03-08 Oreal Procede de preparation de piperidino-6 diamino-2,4 pyrimidine oxyde-3 et composes nouveaux
JPH04211040A (ja) * 1990-02-22 1992-08-03 Sumitomo Pharmaceut Co Ltd トリアミン誘導体及びその酸付加塩
WO1993001498A1 (en) 1991-07-04 1993-01-21 Immunodex K/S Water-soluble, polymer-based reagents and conjugates comprising moieties derived from divinyl sulfone
IT1250749B (it) * 1991-08-02 1995-04-21 Luso Farmaco Inst Composti eterociclici ad attivita' a ii antagonista
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
IL112795A (en) 1994-03-04 2001-01-28 Astrazeneca Ab Derivatives of peptides as antithrombotic drugs, their preparation, and pharmaceutical preparations containing them
AU7692996A (en) 1995-12-01 1997-06-27 Ciba-Geigy Ag Receptor antagonists
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
EP1007073A4 (en) 1996-06-04 2002-03-27 Synaptic Pharma Corp METHODS OF MODIFYING FOOD BEHAVIOR, COMPOUNDS USEFUL IN SAID METHODS, AND DNA ENCODING A HYPOTHALAMIC NEUROPEPTIDE Y / PEPTIDE YY Y5 RECEPTOR
NO311614B1 (no) 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
JP2002514195A (ja) 1996-12-05 2002-05-14 アムジエン・インコーポレーテツド 置換ピリミジン化合物およびそれの使用
JP2001518094A (ja) * 1997-03-31 2001-10-09 デュポン ファーマシューティカルズ カンパニー Ｈｉｖプロテアーゼ阻害剤として有用なインダゾール−環式尿素
CA2333927A1 (en) 1998-04-01 1999-10-07 Dupont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
CN1312807A (zh) * 1998-06-19 2001-09-12 希龙公司 糖元合成酶激酶3的抑制剂
ATE291423T1 (de) 1998-08-20 2005-04-15 Agouron Pharma Nicht-peptidische gnrh agentia, verfahren und zwischenverbindungen zur ihren herstellung
DE19851421A1 (de) * 1998-11-07 2000-05-11 Boehringer Ingelheim Pharma Neue Pyrimidine, deren Herstellung und Verwendung
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
US6274588B1 (en) 1999-05-31 2001-08-14 Hoffmann-La Roche Inc. 4-phenyl-pyrimidine derivatives
WO2001047897A1 (en) * 1999-12-28 2001-07-05 Pharmacopeia, Inc. Cytokine, especially tnf-alpha, inhibitors
KR100889246B1 (ko) 2000-12-21 2009-03-19 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 조성물
JP3795044B2 (ja) 2001-09-14 2006-07-12 メシルジーン、インコーポレイテッド ヒストンデアセチラーゼの阻害剤
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
WO2003026666A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
CN1582281A (zh) 2001-10-01 2005-02-16 大正制药株式会社 Mch受体拮抗剂
AU2003220968A1 (en) * 2002-03-28 2003-10-13 Kyowa Hakko Kogyo Co., Ltd. Anti-inflammatory agent
CA2490888C (en) * 2002-06-28 2011-05-24 Yamanouchi Pharmaceutical Co., Ltd. Diaminopyrimidinecarboxamide derivative
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
MXPA05001096A (es) * 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
EP1565446A1 (en) * 2002-11-28 2005-08-24 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
EP1571146A4 (en) * 2002-12-10 2010-09-01 Ono Pharmaceutical Co NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE
JPWO2004074260A1 (ja) * 2003-02-21 2006-06-01 協和醗酵工業株式会社 ピリミジン誘導体
EP1464335A3 (en) * 2003-03-31 2007-05-09 Taisho Pharmaceutical Co. Ltd. Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist
CA2539159A1 (en) * 2003-09-22 2005-03-31 F. Hoffmann-La Roche Ag Aminoalkylamide substituted cyclohexyl derivatives
JP2007217282A (ja) * 2004-03-04 2007-08-30 Astellas Pharma Inc 置換ピリミジン誘導体
CN106434833A (zh) * 2004-05-23 2017-02-22 杰勒德·M·豪斯 Theramutein调节剂
CA2577947A1 (en) * 2004-08-31 2006-03-09 Banyu Pharmaceutical Co., Ltd. Novel substituted imidazole derivative
CA2585615C (en) * 2004-11-03 2013-11-26 F. Hoffmann-La Roche Ag Dicarboxamide derivatives and their use as factor xa inhibitors
JP2006188445A (ja) * 2005-01-05 2006-07-20 Ono Pharmaceut Co Ltd 含窒素複素環化合物およびその医薬用途
EP1852432A4 (en) * 2005-02-25 2010-04-14 Ono Pharmaceutical Co NITROGENIC HETEROCYCLIC COMPOUND AND THEIR MEDICAL USE
KR20080090381A (ko) * 2005-08-29 2008-10-08 제라드 엠. 하우지 테라뮤틴 조절물질
KR101415426B1 (ko) * 2005-09-27 2014-07-04 아이알엠 엘엘씨 디아릴아민-함유 화합물 및 조성물, 및 ｃ-ｋｉｔ 수용체의조절제로서의 그의 용도
JP2009523408A (ja) * 2005-11-23 2009-06-25 ジェラルド・エム・ハウシー タンパク質モジュレーターを同定、合成、最適化および解析する化合物群および方法群
UY30117A1 (es) * 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
EP2001864A1 (en) * 2006-03-16 2008-12-17 Novartis Pharma AG Heterocyclic organic compounds for the treatment of in particular melanoma
WO2007129195A2 (en) * 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034560A (en) * 1990-10-19 1991-07-23 The Standard Oil Company Synthesis of ethylamines
US6420354B1 (en) * 1998-06-08 2002-07-16 Advanced Medicine, Inc. Sodium channel drugs and uses
US7501412B2 (en) * 2002-11-22 2009-03-10 Mitsubishi Tanabe Pharma Corporation Isoquinoline compounds and medicinal use thereof
US20050124640A1 (en) * 2003-01-30 2005-06-09 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta
US20060293324A1 (en) * 2005-06-14 2006-12-28 Chi-Feng Yen Pyrimidine compounds

Cited By (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090143302A1 (en) * 2005-06-14 2009-06-04 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
US20060293324A1 (en) * 2005-06-14 2006-12-28 Chi-Feng Yen Pyrimidine compounds
US7589197B2 (en) 2005-06-14 2009-09-15 Taigen Biotechnology Pyrimidine compounds
US9365548B2 (en) 2006-03-31 2016-06-14 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor
US8343989B2 (en) 2006-03-31 2013-01-01 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor
US20100256373A1 (en) * 2006-03-31 2010-10-07 Edwards James P Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor
US8598189B2 (en) 2006-03-31 2013-12-03 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor
US8962644B2 (en) 2006-03-31 2015-02-24 Janssen Pharmaceutica, Nv Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor
WO2007132846A1 (ja) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. 保護されていてもよい酸性基を含有する化合物およびその用途
WO2008016006A1 (en) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
US20100069368A1 (en) * 2007-03-15 2010-03-18 Miao Dai Organic Compounds and Their Uses
US8536168B2 (en) 2007-03-15 2013-09-17 Novartis Ag Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway
AU2008225766B2 (en) * 2007-03-15 2012-06-07 Novartis Ag Organic compounds and their uses
WO2008152223A1 (fr) * 2007-05-04 2008-12-18 Ipsen Pharma S.A.S. Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatase cdc25
US20100137275A1 (en) * 2007-05-04 2010-06-03 Ipsen Pharma S.A.S. Triaminopyrimidine derivatives as inhibitors of cdc25 phosphatase
FR2915747A1 (fr) * 2007-05-04 2008-11-07 Sod Conseils Rech Applic Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatase cdc25
US8293757B2 (en) 2007-08-22 2012-10-23 Irm Llc 5-(4-(haloalkoxy)phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
EA019289B1 (ru) * 2008-04-21 2014-02-28 Тайджен Байотекнолоджи Ко., Лтд. Производные аминопиридина, аминопиримидина и амино-1,3,5-триазина
WO2009131598A1 (en) 2008-04-21 2009-10-29 Taigen Biotechnology Co., Ltd. Heterocyclic compounds
US20090264339A1 (en) * 2008-04-21 2009-10-22 Taigen Biotechnology Co., Ltd. Heterocyclic Compounds
US8372849B2 (en) * 2008-04-21 2013-02-12 Taigen Biotechnology Co., Ltd. Heterocyclic compounds
AU2008355098B2 (en) * 2008-04-21 2012-11-15 Gpcr Therapeutics, Inc Heterocyclic compounds
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
US8481542B2 (en) 2008-07-18 2013-07-09 Novartis Ag Pyridazinyl derivatives as smo inhibitors
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
US9409871B2 (en) 2008-07-18 2016-08-09 Novartis Ag Pyridazinyl derivatives as SMO inhibitors
WO2010020432A3 (en) * 2008-08-22 2010-04-29 Biomarin Iga Limited Compounds for treatment of duchenne muscular dystrophy
WO2010020432A2 (en) * 2008-08-22 2010-02-25 Summit Corporation Plc Compounds for treatment of duchenne muscular dystrophy
US9023834B2 (en) * 2008-11-13 2015-05-05 Taigen Biotechnology Co., Ltd. Lyophilization formulation
US20100120719A1 (en) * 2008-11-13 2010-05-13 Taigen Biotechnology Co., Ltd. Lyophilization formulation
WO2010056847A2 (en) * 2008-11-13 2010-05-20 Taigen Biotechnology Co., Ltd. Lyophilization formulation
WO2010056847A3 (en) * 2008-11-13 2010-09-16 Taigen Biotechnology Co., Ltd. Lyophilization formulation
WO2010130900A3 (fr) * 2009-05-15 2011-04-07 Ipsen Pharma S.A.S. Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatases cdc25
FR2945530A1 (fr) * 2009-05-15 2010-11-19 Ipsen Pharma Sas Derives de tri-amino-pyridine comme inhibiteurs de phosphatases cdc25
FR2945532A1 (fr) * 2009-05-15 2010-11-19 Ipsen Pharma Sas Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatases cdc25
EP2510926A4 (en) * 2009-12-08 2013-08-21 Inst Radiation Med Amms Pla USE OF SATURATED AMINE COMPOUNDS IN THE MANUFACTURE OF MEDICAMENTS FOR MOBILIZING BLOOD-GENERATING STEM CELLS IN THE PERIPHERAL BLOOD
JP2013512932A (ja) * 2009-12-08 2013-04-18 中国人民解放軍軍事医学科学院野戦輸血研究所 末梢血造血幹細胞動員剤の生産における飽和アミン化合物の使用
EP2510926A1 (en) * 2009-12-08 2012-10-17 Institute of Radiation Medicine Academy of Military Medical Sciences of the Pla Use of saturated amines compounds in manufacture of medicaments for mobilizing peripheral blood hematopoietic stem cell
US9045461B2 (en) 2010-02-18 2015-06-02 Transtech Pharma, Llc Phenyl-heteroaryl derivatives and methods of use thereof
US8741900B2 (en) 2010-02-18 2014-06-03 Transtech Pharma, Llc Phenyl-heteroaryl derivatives and methods of use thereof
US8431575B2 (en) 2010-02-18 2013-04-30 Transtech Pharma, Inc. Phenyl-heteroaryl derivatives and methods of use thereof
US20110230458A1 (en) * 2010-02-18 2011-09-22 Transtech Pharma, Inc. Phenyl-heteroaryl derivatives and methods of use thereof
WO2011157397A1 (en) 2010-06-15 2011-12-22 Almirall, S.A. Heteroaryl imidazolone derivatives as jak inhibitors
EP2397482A1 (en) 2010-06-15 2011-12-21 Almirall, S.A. Heteroaryl imidazolone derivatives as jak inhibitors
US8859575B2 (en) 2013-03-06 2014-10-14 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
US9278952B2 (en) 2013-03-06 2016-03-08 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine H4 receptor
US9434715B2 (en) 2013-03-06 2016-09-06 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine H4 receptor
US9663497B2 (en) 2013-03-06 2017-05-30 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine H4 receptor
US11254681B2 (en) 2014-08-04 2022-02-22 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
US10683293B2 (en) 2014-08-04 2020-06-16 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
US10689383B2 (en) 2014-08-04 2020-06-23 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
US10351553B2 (en) 2017-01-23 2019-07-16 Cadent Therapeutics, Inc. Potassium channel modulators
US10717728B2 (en) 2017-01-23 2020-07-21 Cadent Therapeutics, Inc. Potassium channel modulators
US9975886B1 (en) 2017-01-23 2018-05-22 Cadent Therapeutics, Inc. Potassium channel modulators
US11993586B2 (en) 2018-10-22 2024-05-28 Novartis Ag Crystalline forms of potassium channel modulators
US11447479B2 (en) 2019-12-20 2022-09-20 Nuevolution A/S Compounds active towards nuclear receptors
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors
US11780843B2 (en) 2020-03-31 2023-10-10 Nuevolution A/S Compounds active towards nuclear receptors

Also Published As

Publication number Publication date
EA200800047A1 (ru) 2008-08-29
TWI376376B (en) 2012-11-11
JP5118029B2 (ja) 2013-01-16
EA015890B1 (ru) 2011-12-30
EP1890703A2 (en) 2008-02-27
WO2006138304A2 (en) 2006-12-28
KR101354114B1 (ko) 2014-01-24
CA2612227A1 (en) 2006-12-28
US20060293324A1 (en) 2006-12-28
HK1121062A1 (en) 2009-04-17
US7589197B2 (en) 2009-09-15
EP1890703A4 (en) 2010-11-03
EP1890703B1 (en) 2016-05-11
AU2006259525A1 (en) 2006-12-28
KR20080036038A (ko) 2008-04-24
NZ564222A (en) 2011-10-28
WO2006138304A3 (en) 2007-05-24
TW200716612A (en) 2007-05-01
AU2006259525B2 (en) 2012-05-24
JP2008546698A (ja) 2008-12-25
CA2612227C (en) 2014-04-22

Similar Documents

Publication Publication Date Title
US7589197B2 (en) Pyrimidine compounds
US8193206B2 (en) Pyrimidine compounds
US8153625B2 (en) Nitrogen-containing heterocyclic compounds and medicinal use thereof
AU2003295776B2 (en) 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
US8372849B2 (en) Heterocyclic compounds
US7700624B2 (en) 3-aminocyclopentanecrboxamides as modulators of chemokine receptors
US20080108616A1 (en) Compounds and compositions as protein kinase inhibitors
US8268826B2 (en) Piperazinylpiperidine derivatives as chemokine receptor antagonists
US7125997B2 (en) Differential tumor cytotoxicity compounds and compositions
US7399776B2 (en) Polyamine compounds for treating chemokine receptor mediated diseases
US7501526B2 (en) Synthesis of polyamine compounds
WO2009012259A1 (en) Pentafluorosulfanyl-substituted piperazinylpiperidine derivatives as chemokine receptor antagonists

Legal Events

Date Code Title Description
AS Assignment

Owner name: TAIGEN BIOTECHNOLOGY, TAIWAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YEN, CHI-FENG;HU, CHENG-KUNG;CHOU, MING-CHEN;AND OTHERS;REEL/FRAME:018756/0557

Effective date: 20060605

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION